ClinicalTrials.gg
CompletedNCT05897541SCORPIO-PEPUpdated Oct 7, 2026Results posted

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

A Phase 3 interventional study of S-217622 and Placebo in SARS-CoV-2 Infection, sponsored by Shionogi. Completed at 178 sites in 5 countries. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,701
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
76th of 1,321
3,701 · median 91
Started
2023
with 130 others
Phase 3
174 of 1,859
11 open now
Registered
1,655th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 76th largest by enrollment of the 1,321 interventional ones that give a count, is one of 131 that started in 2023, is one of 174 in phase 3, and was the 1,655th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction [RT-PCR] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 tablets compared with placebo tablets in participants who are household contacts of an individual with symptomatic COVID-19.

Read the detailed description

This study will enroll 2 types of participants: 1. those with a negative screening SARS-CoV-2 infection (referred to as "study participants"); 2. those with a positive screening SARS-CoV-2-infection (referred to as "index participants"). Study participants will receive study intervention (S-217622 or placebo), index participants will receive no study intervention. A total of 3701 participants will be enrolled in the study, of whom 2387 will be randomized to receive study drug or placebo, and 1314 will be enrolled as index case participants.

03

Conditions studied

  • SARS-CoV-2 Infection

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Index Participants

Only 1 index participant from each household will be enrolled in the study. Participants are eligible to be included as an index participant if all of the following criteria apply:

  1. Pediatric participants or adult participants (of any age)
  2. The index participant must:

    1. Have at least 1 COVID-19 symptom within 24 hours before the index participant providing . COVID-19 symptom(s) must be deemed by the investigator as related to the current SARS-CoV-2 infection (not related to preexisting comorbidities) or deemed as preexisting and worsened due to SARS-CoV-2 infection.
    2. Must have positive SARS-CoV-2 test (a nucleic acid amplification test or antigen test) from any respiratory tract specimen from a sample collected prior to randomization of the participant
  3. Must have a potential study participant who can participate in the study after onset of COVID-19 symptoms in an index participant

Study Participants

Multiple study participants from the same household are allowed to be enrolled in the study. The study intervention randomization will be performed based at the study participant's level. Participants will be eligible to be included in the study only if all of the following criteria apply:

  1. ≥ 12 years of age at the time of signing the informed consent
  2. Has a negative screening for SARS-CoV-2 infection, as determined by SARS-CoV-2 test (a nucleic acid amplification test or antigen test) from any respiratory tract specimen (for example, oropharyngeal, nasopharyngeal or nasal swab, or saliva).
  3. Has lived in household with index participant and will continue to live in same household and share common areas such as dining rooms and bathrooms until the end of the study
  4. Must not be considered by the investigator or subinvestigator to have SARS-CoV-2 infection and:

    1. No measured fever at Screening (defined as body temperature ≥ 38.0°Celsius [C] per tympanic or rectal thermometer or ≥ 37.5°C per axillary, oral, or forehead/temporal thermometer)
    2. No COVID-19 symptoms at Screening (if a participant has COVID-19-like symptoms caused by comorbidities, only 1 symptom will be allowed)
  5. Capable and willing to complete a participant diary
  6. a. Male participants: Participants with partners that are woman of (WOCBP) must agree to use effective . Participants with pregnant partners must agree to use effective contraception.

    b. Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and the following conditions applies:

    • Is not a WOCBP or
    • All of the following apply:

      • Is a WOCBP and using a contraceptive method that is effective as described in the protocol.
      • A WOCBP must have a negative urine pregnancy test within 24 hours before the first dose of study intervention period.
      • If a urine pregnancy test cannot be confirmed as negative (for example, an ambiguous result), a serum pregnancy test must be negative.
    • Additional requirements for pregnancy testing during and after study intervention as described in the protocol.
    • The investigator/subinvestigator will review medical history, menstrual history, and recent sexual activity to decrease the risk of inclusion of a woman with an early undetected pregnancy.
  7. Participant must be randomized ≤ 72 hours from onset of COVID-19 symptoms in the index participant.

Exclusion criteria

Exclusion Criteria:

Study Participants: Participants will be excluded from the study if any of the following criteria apply:

  1. Tested positive for SARS-CoV-2 in the past 6 months.
  2. Have an underlying disease requiring systemic (excluding topical), antipyretics/analgesics, or agents.
  3. Known current renal impairment defined as \< 30 milliliters/minute by Cockcroft Gault or requiring dialysis.
  4. Participants with severe liver dysfunction, such as known history of cirrhosis or liver decompensation (including ascites, variceal bleeding, or hepatic encephalopathy).
  5. Received approved, authorized, or convalescent plasma, or other anti- SARS-CoV-2 biologic products within 3 months of the Screening Visit
  6. Received approved, authorized, or investigational anti-SARS-CoV-2 monoclonal antibodies (mAbs) in the last 6 months.
  7. Received any SARS-CoV-2 vaccine within 6 months prior to the Screening Visit or is expected to receive a SARS-CoV-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments until the end of the study.
  8. Participants who have used any of the following drugs within 14 days prior to enrollment:

    1. Strong cytochrome P450 (CYP) 3A inducer
    2. Products containing St. John's wort
  9. Exposed to an investigational drug within 30 days or 5 half-lives of the drug prior to the Screening Visit.
  10. Positive urine pregnancy test at Screening Visit or are lactating.
  11. Known allergy/sensitivity or any to components of S-217622 or placebo for S-217622.
  12. Any condition or circumstance that, in the opinion of the investigator or subinvestigator, would compromise the safety of the participant or the quality of the study data.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,701 participants (actual)

Study arms

  • Experimental
    S-217622

    S-217622 will be administered orally for 5 days.

    Drug: S-217622

  • Placebo comparator
    Placebo

    Placebo matching to S-217622 will be administered orally for 5 days.

    Drug: Placebo

Interventions

  • Administered as a tablet.

    Also known as: XOCOVA, ensitrelvir

  • DrugPlacebo

    Administered as a tablet.

06

What researchers measure

Primary outcomes

  1. Number of Participants in mITT Population Who Were Infected With SARS-CoV-2 and Had Coronavirus Disease 2019 (COVID-19) Symptoms Onset

    Symptomatic COVID-19 was defined as a central laboratory-confirmed (CLC) positive reverse transcription polymerase chain reaction (RT-PCR) test and the occurrence (or worsening \[increasing a symptom score from baseline\] in the case of preexisting COVID-19-like symptoms) of \>= 1 of the 14 specified COVID-19 symptoms for at least 48 hours.

    Time frame: Day 1 up to Day 10

Secondary outcomes

  1. Number of Participants in ITT Population With a Negative Screening SARS-CoV-2 Infection Who Were Infected With SARS-CoV-2 and Had COVID-19 Symptoms Onset

    Symptomatic COVID-19 was defined as a CLC positive RT-PCR test and the occurrence (or worsening \[increasing a symptom score from baseline\] in the case of preexisting COVID-19-like symptoms) of \>= 1 of the 14 specified COVID-19 symptoms for at least 48 hours.

    Time frame: Day 1 up to Day 10

  2. Number of Participants Infected With SARS-CoV-2 Regardless of Occurrence of COVID-19 Symptoms

    COVID-19 with or without symptoms onset was defined as any post baseline CLC-positive RT-PCR test.

    Time frame: Days 10, 15 and 28

  3. Time to the First Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Result

    Time frame: Day 1 up to Day 28

  4. Number of Participants With a Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Results

    Time frame: Day 1 up to Day 10

  5. Number of Participants Infected With SARS-CoV-2 With no COVID-19 Symptoms at Day 10

    Asymptomatic COVID-19 was defined as: Incident SARS-CoV-2 infection between first study intervention administration and Day 10 visit, as confirmed by CLC positive RT-PCR test, no negative RT-PCR test between (1) the day of the first positive test and (2) Day 10 visit after the first study intervention and no COVID-19 symptoms occurrence on Day 10 (or if Day 10 is missing, no symptoms recorded on the most recent diary entry prior to Day 10).

    Time frame: Day 10

  6. Number of Participants Infected With SARS-CoV-2 and Had no COVID-19 Symptoms Onset Through Day 10

    COVID-19 without symptoms onset was defined as any post-baseline CLC positive RT-PCR result through the Day 10 visit (up to day 11), but without any new or worsening symptoms having duration \>=48 hours starting by day 10.

    Time frame: Day 1 up to Day 10

  7. Number of Participants With Sustained Symptom Resolution of Each COVID-19 Symptoms

    Sustained symptoms resolution was defined as \>=48 hours with each symptom (except loss of taste and loss of smell) having an equal or lower symptom score relative to that symptom's baseline value.

    Time frame: Day 1 up to Day 28

  8. Change From Baseline in Total Symptom Score of COVID-19 Symptoms at Day 10

    Total symptom score was defined as the sum of scores for all 14 targeted symptoms (each individual symptom score was 0 = none, 1 = mild, 2 = moderate, and 3 = severe), where total score ranged 0 (none)-42 (severe symptom) and higher scores indicated severe symptoms.

    Time frame: Baseline, Day 10

  9. Time From First Central Laboratory Confirmed SARS-CoV-2 Until at Least 1 COVID-19 Symptom

    Time from CLC positive RT-PCR test to time of first symptoms diary reporting at least 1 COVID-19 symptom with greater-than-baseline severity through Day 28 has been reported.

    Time frame: Day 1 up to Day 28

  10. Time From First Central Laboratory Confirmed SARS-CoV-2 Until COVID-19 Symptoms Onset

    COVID-19 symptoms onset was defined as the occurrence (or worsening \[increasing a symptom score from baseline\] in the case of preexisting COVID-19-like symptoms) of \>= 1 of the 14 specified COVID-19 symptoms for at least 48 hours.

    Time frame: Day 1 up to Day 28

  11. Number of Participants Experiencing Hospitalization or Death From Any Cause

    Hospitalization was defined as \>=24 hours of acute care for any reason, in a hospital or similar acute care facility, including emergency rooms or urgent care clinics. The participants reported below were hospitalized. No participants died in the study.

    Time frame: Day 1 up to Day 28

  12. Trough Concentration (Ctrough) of S-217622

    Time frame: Day 3

  13. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. A TEAE was defined as an AE reported after the first dose of study intervention. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Day 1 up to Day 28

07

Results

Posted Sep 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneS-217622PlaceboIndex Case Participants
Started119411931314
Received at least 1 dose of study drug119011870
Modified intention-to-treat (mitt) analysis set103010110
Intent to treat (itt)119411930
Completed117211581314
Not completed22350
Withdrew: Other than specified310
Withdrew: Lost to follow-up670
Withdrew: Withdrawal by subject12250
Withdrew: Protocol violation010
Withdrew: Adverse event010
Withdrew: Failure to meet eligibility criteria100

Outcome measures

PrimaryNumber of Participants in mITT Population Who Were Infected With SARS-CoV-2 and Had Coronavirus Disease 2019 (COVID-19) Symptoms Onset

Symptomatic COVID-19 was defined as a central laboratory-confirmed (CLC) positive reverse transcription polymerase chain reaction (RT-PCR) test and the occurrence (or worsening \[increasing a symptom score from baseline\] in the case of preexisting COVID-19-like symptoms) of \>= 1 of the 14 specified COVID-19 symptoms for at least 48 hours.

Time frame:
Day 1 up to Day 10
Reported as:
Count of participants · Participants
Number of Participants in mITT Population Who Were Infected With SARS-CoV-2 and Had Coronavirus Disease 2019 (COVID-19) Symptoms Onset
ParticipantsS-217622Placebo
Number of Participants in mITT Population Who Were Infected With SARS-CoV-2 and Had Coronavirus Disease 2019 (COVID-19) Symptoms Onset3091
SecondaryNumber of Participants in ITT Population With a Negative Screening SARS-CoV-2 Infection Who Were Infected With SARS-CoV-2 and Had COVID-19 Symptoms Onset

Symptomatic COVID-19 was defined as a CLC positive RT-PCR test and the occurrence (or worsening \[increasing a symptom score from baseline\] in the case of preexisting COVID-19-like symptoms) of \>= 1 of the 14 specified COVID-19 symptoms for at least 48 hours.

Time frame:
Day 1 up to Day 10
Reported as:
Count of participants · Participants
Number of Participants in ITT Population With a Negative Screening SARS-CoV-2 Infection Who Were Infected With SARS-CoV-2 and Had COVID-19 Symptoms Onset
ParticipantsS-217622Placebo
Number of Participants in ITT Population With a Negative Screening SARS-CoV-2 Infection Who Were Infected With SARS-CoV-2 and Had COVID-19 Symptoms Onset52122
SecondaryNumber of Participants Infected With SARS-CoV-2 Regardless of Occurrence of COVID-19 Symptoms

COVID-19 with or without symptoms onset was defined as any post baseline CLC-positive RT-PCR test.

Time frame:
Days 10, 15 and 28
Reported as:
Count of participants · Participants
Number of Participants Infected With SARS-CoV-2 Regardless of Occurrence of COVID-19 Symptoms
ParticipantsS-217622Placebo
Day 10144217
Day 15183261
Day 28253318
SecondaryTime to the First Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Result
Time frame:
Day 1 up to Day 28
Reported as:
Mean · hours
Time to the First Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Result
hoursS-217622Placebo
Time to the First Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Result613.70 ± 7.845558.26 ± 9.672
SecondaryNumber of Participants With a Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Results
Time frame:
Day 1 up to Day 10
Reported as:
Count of participants · Participants
Number of Participants With a Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Results
ParticipantsS-217622Placebo
Number of Participants With a Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Results56131
SecondaryNumber of Participants Infected With SARS-CoV-2 With no COVID-19 Symptoms at Day 10

Asymptomatic COVID-19 was defined as: Incident SARS-CoV-2 infection between first study intervention administration and Day 10 visit, as confirmed by CLC positive RT-PCR test, no negative RT-PCR test between (1) the day of the first positive test and (2) Day 10 visit after the first study intervention and no COVID-19 symptoms occurrence on Day 10 (or if Day 10 is missing, no symptoms recorded on the most recent diary entry prior to Day 10).

Time frame:
Day 10
Reported as:
Count of participants · Participants
Number of Participants Infected With SARS-CoV-2 With no COVID-19 Symptoms at Day 10
ParticipantsS-217622Placebo
Number of Participants Infected With SARS-CoV-2 With no COVID-19 Symptoms at Day 104169
SecondaryNumber of Participants Infected With SARS-CoV-2 and Had no COVID-19 Symptoms Onset Through Day 10

COVID-19 without symptoms onset was defined as any post-baseline CLC positive RT-PCR result through the Day 10 visit (up to day 11), but without any new or worsening symptoms having duration \>=48 hours starting by day 10.

Time frame:
Day 1 up to Day 10
Reported as:
Count of participants · Participants
Number of Participants Infected With SARS-CoV-2 and Had no COVID-19 Symptoms Onset Through Day 10
ParticipantsS-217622Placebo
Number of Participants Infected With SARS-CoV-2 and Had no COVID-19 Symptoms Onset Through Day 10118133
SecondaryNumber of Participants With Sustained Symptom Resolution of Each COVID-19 Symptoms

Sustained symptoms resolution was defined as \>=48 hours with each symptom (except loss of taste and loss of smell) having an equal or lower symptom score relative to that symptom's baseline value.

Time frame:
Day 1 up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Sustained Symptom Resolution of Each COVID-19 Symptoms
ParticipantsS-217622Placebo
Number of Participants With Sustained Symptom Resolution of Each COVID-19 Symptoms1958
SecondaryChange From Baseline in Total Symptom Score of COVID-19 Symptoms at Day 10

Total symptom score was defined as the sum of scores for all 14 targeted symptoms (each individual symptom score was 0 = none, 1 = mild, 2 = moderate, and 3 = severe), where total score ranged 0 (none)-42 (severe symptom) and higher scores indicated severe symptoms.

Time frame:
Baseline, Day 10
Reported as:
Mean · scores on a scale
Change From Baseline in Total Symptom Score of COVID-19 Symptoms at Day 10
scores on a scaleS-217622Placebo
Change From Baseline in Total Symptom Score of COVID-19 Symptoms at Day 100.07 ± 0.5250.26 ± 1.318
SecondaryTime From First Central Laboratory Confirmed SARS-CoV-2 Until at Least 1 COVID-19 Symptom

Time from CLC positive RT-PCR test to time of first symptoms diary reporting at least 1 COVID-19 symptom with greater-than-baseline severity through Day 28 has been reported.

Time frame:
Day 1 up to Day 28
Reported as:
Mean · hours
Time From First Central Laboratory Confirmed SARS-CoV-2 Until at Least 1 COVID-19 Symptom
hoursS-217622Placebo
Time From First Central Laboratory Confirmed SARS-CoV-2 Until at Least 1 COVID-19 Symptom464.98 ± 19.863390.74 ± 19.557
SecondaryTime From First Central Laboratory Confirmed SARS-CoV-2 Until COVID-19 Symptoms Onset

COVID-19 symptoms onset was defined as the occurrence (or worsening \[increasing a symptom score from baseline\] in the case of preexisting COVID-19-like symptoms) of \>= 1 of the 14 specified COVID-19 symptoms for at least 48 hours.

Time frame:
Day 1 up to Day 28
Reported as:
Mean · hours
Time From First Central Laboratory Confirmed SARS-CoV-2 Until COVID-19 Symptoms Onset
hoursS-217622Placebo
Time From First Central Laboratory Confirmed SARS-CoV-2 Until COVID-19 Symptoms Onset495.69 ± 18.616394.89 ± 19.525
SecondaryNumber of Participants Experiencing Hospitalization or Death From Any Cause

Hospitalization was defined as \>=24 hours of acute care for any reason, in a hospital or similar acute care facility, including emergency rooms or urgent care clinics. The participants reported below were hospitalized. No participants died in the study.

Time frame:
Day 1 up to Day 28
Reported as:
Count of participants · Participants
Number of Participants Experiencing Hospitalization or Death From Any Cause
ParticipantsS-217622Placebo
Number of Participants Experiencing Hospitalization or Death From Any Cause20
SecondaryTrough Concentration (Ctrough) of S-217622
Time frame:
Day 3
Reported as:
Geometric mean · microgram/milliliters
Trough Concentration (Ctrough) of S-217622
microgram/millilitersS-217622
Trough Concentration (Ctrough) of S-21762212.802 ± 61.4
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. A TEAE was defined as an AE reported after the first dose of study intervention. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Day 1 up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsS-217622Placebo
Number of Participants With Treatment-emergent Adverse Events (TEAEs)180184

Adverse events

Collected over Day 1 up to Day 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
S-2176220/1,190 (0%)3/1,190 (0.3%)0/1,190 (0%)
Placebo0/1,187 (0%)2/1,187 (0.2%)0/1,187 (0%)
Most frequent serious events
Most frequent serious events
EventS-217622Placebo
ColitisGastrointestinal disorders0/11901/1187
Hepatic enzyme increasedInvestigations0/11901/1187
Umbilical HerniaGastrointestinal disorders1/11900/1187
PneumoniaInfections and infestations1/11900/1187
Urinary Tract InfectionInfections and infestations1/11900/1187

Baseline characteristics

Randomized HHC participants: Safety analysis set included all participants randomly assigned to study intervention who received at least 1 dose of study intervention. Index case participants: All index participants who had met all eligibility requirements with a signed informed consent and were associated with 1 or more participants who were randomized to receive a study intervention and who did not have any exclusionary deviations.

Age, Categorical
Age, Categorical(Participants)S-217622PlaceboIndex Case ParticipantsTotal
<=18 years7267212351
Between 18 and 65 years100410029652971
>=65 years114118137369
Sex: Female, Male
Sex: Female, Male(Participants)S-217622PlaceboIndex Case ParticipantsTotal
Female6857307382153
Male5054575761538
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)S-217622PlaceboIndex Case ParticipantsTotal
Hispanic or Latino7087156202043
Not Hispanic or Latino4824726941648
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)S-217622PlaceboIndex Case ParticipantsTotal
American Indian or Alaska Native3429
Asian3763765731325
Native Hawaiian or Other Pacific Islander0011
Black or African American606367190
White7287236522103
More than one race0000
Unknown or Not Reported23211963
08

Study locations

178 sites
  • Central Alabama Research
    Birmingham, Alabama 35209-8401, United States
  • Accel Research Site - Achieve - Birmingham - ERN - PPDS
    Birmingham, Alabama 35216, United States
  • Cullman Clinical Trials
    Cullman, Alabama 35055-1902, United States
  • Absolute Clinical Research, LLC
    Phoenix, Arizona 85051-5775, United States
  • One of a Kind Clinical Research Center LLC
    Scottsdale, Arizona 85258-4590, United States
  • Healthstar Research
    Hot Springs, Arkansas 71913-8184, United States
  • Preferred Research Partners - ClinEdge - PPDS
    Little Rock, Arkansas 72211-3868, United States
  • Neighborhood Healthcare
    Escondido, California 92025-4604, United States
  • Apex Research Group
    Fair Oaks, California 95628-2501, United States
  • Ascada Research LLC
    Fullerton, California 92835-4127, United States
  • Torrance Clinical Research Institute
    Lomita, California 90717-2101, United States
  • Ark Clinical Research - Long Beach - ClinEdge - PPDS
    Long Beach, California 90815-2521, United States
  • Rancho Cucamonga Clinical Research
    Rancho Cucamonga, California 91730-3062, United States
  • Smart Cures Clinical Research
    Rolling Hills Estates, California 90274-7604, United States
  • Clinical Trials Management Services, LLC
    Thousand Oaks, California 91360, United States
  • Lynn Institute of The Rockies - ERN - PPDS
    Colorado Springs, Colorado 80918-1662, United States
  • TrueBlue Clinical Research
    Brandon, Florida 33511-4850, United States
  • Invictus Clinical Research Group, LLC
    Coconut Creek, Florida 33073-3458, United States
  • Universal Medical and Research Center, LLC
    Coral Gables, Florida 33134-1602, United States
  • Hope Clinical Trials
    Coral Gables, Florida 33134-1642, United States
  • I.V.A.M. Clinical & Investigational Center
    Doral, Florida 33126, United States
  • Quality Research of South Florida
    Hialeah, Florida 33016-1811, United States
  • Universal Medical and Research Center, LLC Homestead
    Homestead, Florida 33030-6057, United States
  • Flourish Research - Leesburg - PPDS
    Leesburg, Florida 34748-5077, United States
  • Premier Clinical Research Institute - Miami - ClinEdge - PPDS
    Miami, Florida 33122-1335, United States
  • LCC Medical Research - Miami - ClinEdge - PPDS
    Miami, Florida 33126-1921, United States
  • CCM Clinical Research Group
    Miami, Florida 33133-4231, United States
  • Suncoast Research Group LLC - Flourish - PPDS
    Miami, Florida 33135-1687, United States
  • University of Miami - 1150 NW 14th St
    Miami, Florida 33136-1104, United States
  • Florida Research Center, Inc.
    Miami, Florida 33144-2069, United States
  • Oceane7 Medical & Research Center, Inc.
    Miami, Florida 33144-2155, United States
  • Continental Clinical Research, LLC
    Miami, Florida 33144-4273, United States
  • BioClinical Research Alliance
    Miami, Florida 33155-6542, United States
  • Ivetmar Medical Group, LLC
    Miami, Florida 33155-6542, United States
  • Miami Clinical Research - ClinEdge - PPDS
    Miami, Florida 33155, United States
  • Global Health Clinical Trials
    Miami, Florida 33165-2968, United States
  • Valencia Medical and Research Center
    Miami, Florida 33165-3912, United States
  • Alma Research
    Miami, Florida 33165, United States
  • GCP Global Clinical Professionals, LLC
    Miami, Florida 33169-5732, United States
  • Research Institute of South Florida Inc
    Miami, Florida 33173-4648, United States
  • Entrust Clinical Research
    Miami, Florida 33176-1530, United States
  • Kendall South Medical Center
    Miami, Florida 33185-4082, United States
  • Flourish Research - Miami - PPDS
    Miami, Florida 33186-9066, United States
  • Meridian International Research
    Miami Lakes, Florida 33014-6433, United States
  • MedQuest Translational Sciences
    Miami Lakes, Florida 33016, United States
  • Combined Research Orlando Phase I-IV LLC
    Orlando, Florida 32807-3555, United States
  • Central Florida Internists - Conway
    Orlando, Florida 32812-7331, United States
  • Accel Research Sites - Nona Pediatric Center - ERN - PPDS
    Orlando, Florida 32829-8070, United States
  • Ormond Beach Clinical Research
    Ormond Beach, Florida 32174-8196, United States
  • CTMD Research, Inc. Palm Springs - Hunt - PPDS
    Palm Springs, Florida 33406-7671, United States
  • American Research Centers of Florida
    Pembroke Pines, Florida 33027-1717, United States
  • Progressive Medical Research - ClinEdge - PPDS
    Port Orange, Florida 32127, United States
  • Renew Health Clinical Research, LLC
    Tampa, Florida 33607-2529, United States
  • Bayside Clinical Research-West Tampa
    Tampa, Florida 33607, United States
  • Tampa Bay Health Care
    Tampa, Florida 33615, United States
  • Balanced Life Health Care Solutions - SKYCRNG - PPDS
    Lawrenceville, Georgia 30046-8703, United States
  • Olivo Medical and Wellness Center
    Chicago, Illinois 60618-8101, United States
  • Eagle Clinical Research
    Chicago, Illinois 60621-3116, United States
  • KU Wichita Center for Clinical Research
    Wichita, Kansas 67214-3124, United States
  • Voyage Medical - Michigan
    Canton, Michigan 48188-2866, United States
  • Vida Clinical Sites
    Dearborn Heights, Michigan 48127-2234, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202-2608, United States
  • Velocity Clinical Research - Covington - PPDS
    Gulfport, Mississippi 39503-2637, United States
  • Montana Medical Research
    Missoula, Montana 59808, United States
  • Child Healthcare Associates - East Syracuse
    East Syracuse, New York 13057-9305, United States
  • Rochester Clinical Research - ATLAS - Rochester - PPDS
    Rochester, New York 14609-3173, United States
  • Lapis Clinical Research-Denver
    Denver, North Carolina 28037-8254, United States
  • Progressive Medicine of the Triad, LLC
    Winston-Salem, North Carolina 27103-1552, United States
  • WellNow Urgent Care & Research - Huber Heights
    Dayton, Ohio 45424-4019, United States
  • PriMed Clinical Research - ClinEdge - PPDS
    Dayton, Ohio 45429-3658, United States
  • Cyn3rgy Research - ClinEdge - PPDS
    Gresham, Oregon 97030-8319, United States
  • Tristar Clinical Investigations, P.C.
    Philadelphia, Pennsylvania 19114-1030, United States
  • Frontier Clinical Research - Scottdale
    Scottdale, Pennsylvania 15683-2460, United States
  • Coastal Pediatric Associates
    Charleston, South Carolina 29414-5834, United States
  • SPICA Clinical Research
    Columbia, South Carolina 29223-6301, United States
  • Main Street Physicians Care - Waterway
    Little River, South Carolina 29566, United States
  • Clinical Trials of South Carolina - ClinEdge - PPDS
    Moncks Corner, South Carolina 29461-5017, United States
  • Saint Hope Foundation Inc
    Bellaire, Texas 77401-4500, United States
  • ACRC Trials - Carrollton - Hunt - PPDS
    Carrollton, Texas 75010, United States
  • Global Medical Research - M3 WR
    Dallas, Texas 75224-2367, United States
  • Alina Clinical Trials, LLC
    Dallas, Texas 75225-6301, United States
  • Southwest Family Medicine Associates
    Dallas, Texas 75235-1715, United States
  • Epic Medical Research LLC - DeSoto
    DeSoto, Texas 75115-2043, United States
  • Care United Research, LLC - Elligo - PPDS
    Forney, Texas 75126-4174, United States
  • Valley Institute of Research
    Fort Worth, Texas 76164-9041, United States
  • C & R Research Services USA
    Houston, Texas 77022, United States
  • New Horizon Medical Group, LLC
    Houston, Texas 77065, United States
  • Care and Cure Clinic
    Houston, Texas 77090-1243, United States
  • DCT-McAllen Primary Care Research, LLC dba Discove
    McAllen, Texas 78503-1397, United States
  • Advances In Health Inc
    Pearland, Texas 77584-8075, United States
  • Clinical Associates in Research Therapeutics of America
    San Antonio, Texas 78212-4829, United States
  • VIP Trials
    San Antonio, Texas 78230, United States
  • Tranquil Clinical Research
    Webster, Texas 77598-3900, United States
  • Alliance for Multispecialty Research, LLC - Kaysville - PPDS
    Kaysville, Utah 84037-4300, United States
  • Alliance for Multispecialty Research LLC - Roy
    Roy, Utah 84067-9108, United States
  • Hospital Interzonal General de Agudos Vicente Lopez Y Planes
    General Rodriguez, Buenos Aires 1748, Argentina
  • Clínica Privada Independencia
    Munro, Buenos Aires 1605, Argentina
  • Centro Médico San Nicolás Grupo Oroño
    San Nicolás de los Arroyos, Buenos Aires B2900, Argentina
  • Instituto de Investigaciones Clínicas Zárate
    Zárate, Buenos Aires B2800DGH, Argentina
  • Instituto Médico Río Cuarto
    Río Cuarto, Córdoba Province 5800, Argentina

Showing the first 100 of 178 sites across 5 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hayden FG, Shinkai M, Clark TW, Luetkemeyer AF, Sax PE, Hanage WP, Gebo KA, Ikematsu H, Izumikawa K, Fukushi A, Kezbor S, Sakaguchi H, Lacey S, Ichihashi G, Ohmagari N, Uehara T; SCORPIO-PEP Study Team. Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts. N Engl J Med. 2026 May 14;394(19):1905-1915. doi: 10.1056/NEJMoa2509306. PubMed 42127390 ↗
  • Toselli F, Jacobs S, Scheers E, Jacobs T, Doijen J, Hereijgers J, Keustermans K, Aerts L, van Heerden M, Van Loock M, Mason S, Monshouwer M, Van Damme E, Herschke F. Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals. Antiviral Res. 2026 Apr;248:106363. doi: 10.1016/j.antiviral.2026.106363. Epub 2026 Feb 9. PubMed 41672106 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Aug 2024, 14 months.

Results were first posted in Sep 2026, 2 years after primary completion. A results delay was requested in Aug 2025.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 14 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Jun 9, 2023
StartActual
Jun 9, 2023
Primary completionActual
Aug 30, 2024
CompletionActual
Sep 18, 2024
Results delay requested
Aug 4, 2025
Results first posted
Sep 16, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: arm descriptions
1 update, last Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Minor edits only
    + 1 other change: arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05897541
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Jun 9, 2023
Start date
Jun 9, 2023
Primary completion
Aug 30, 2024
Completion
Sep 18, 2024
Results posted
Sep 16, 2026
Last update
Oct 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensitrelvir

Start the discussion